Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.

Bonnet JB, Durieux AT, Tournayre S, Marty L, Sultan A, Avignon A

Obesity research & clinical practice1 Mar 2024

PMID38582735 (opens in a new tab)DOI10.1016/j.orcp.2024.03.009 (opens in a new tab)PepBankPUB-38582735
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 22-year-old woman with mosaic Smith-Kingsmore syndrome and severe obesity, semaglutide was followed by a 9 kg (7.44%) weight loss over 12 months.

    In plain wordsOne young woman with Smith-Kingsmore syndrome and severe obesity lost 9 kg (7.44%) over 12 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss over 12 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Weight loss
    9 kg
    12 months
    Weight loss
    7.44%
    12 months

    Source sentences

    Summary
    She achieved a 9 kg (7.44%) weight loss over 12 months
    1 context sentence
    Summary · context
    We present a 22-year-old woman with mosaic SKS and severe obesity (Body Mass Index ≥40 kg/m²), treated with semaglutide.
  2. 02HumanCase report or seriesSafety outcome

    In a 22-year-old woman with mosaic Smith-Kingsmore syndrome, no adverse effects were reported over 12 months of semaglutide treatment.

    In plain wordsOne young woman with Smith-Kingsmore syndrome reported no side effects over 12 months of semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    without adverse effects
    1 context sentence
    Summary · context
    We present a 22-year-old woman with mosaic SKS and severe obesity (Body Mass Index ≥40 kg/m²), treated with semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.